Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica

Volumn 99, Issue 7, 2014, Pages 1228-1235

  Wilson, Wyndham H ^a   Bromberg, Jacoline E C ^b   Stetler Stevenson, Maryalice ^a   Steinberg, Seth M ^a   Martin Martin, Lourdes ^c   Muñiz, Carmen ^c   Sancho, Juan Manuel ^d   Caballero, Maria Dolores ^c   Davidis, Marjan A ^b   Brooimans, Rik A ^b   Sanchez Gonzalez, Blanca ^e   Salar, Antonio ^e   González Barca, Eva ^d   Ribera, Jose Maria ^d   Shovlin, Margaret ^a   Filie, Armando ^a   Dunleavy, Kieron ^a   Mehrling, Thomas ^f   Spina, Michele ^g   Orfao, Alberto ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c CSIC   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f Mundipharma International Limited   (United Kingdom)

^g CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; HYDROCORTISONE; METHOTREXATE; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID ANALYSIS; CHILD; CONTROLLED STUDY; CYTOLOGY; FEMALE; FLOW CYTOMETRY; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC INDEX; MAJOR CLINICAL STUDY; MALE; OCCULT LEPTOMENINGEAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RISK FACTOR; CANCER STAGING; CEREBROSPINAL FLUID; INTRASPINAL DRUG ADMINISTRATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MENINGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CEREBROSPINAL FLUID; CHILD; FEMALE; FLOW CYTOMETRY; HUMANS; INJECTIONS, SPINAL; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MENINGEAL NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903647717     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.101741     Document Type: Article

References (29)

1. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178-84.
2. Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poorprognosis aggressive non-Hodgkin lymphoma. Blood. 2003;102(13):4284-9.
3. Young RC, Howser DM, Anderson T, Fisher RI, Jaffe E, DeVita VT Jr. Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med. 1979; 66(3):435-43.
4. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502.
5. Schiff D, Feske SK, Wen PY. Deceptively normal ventricular fluid in lymphomatous meningitis. Arch Intern Med. 1993; 153(3):389-90.
6. Glass JP, Melamed M, Chernik NL, Posner JB. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology. 1979;29(10):1369-75.
7. Quijano S, Lopez A, Manuel Sancho J, Panizo C, Deben G, Castilla C, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462-9.
8. Bromberg JE, Breems DA, Kraan J, Bikker G, van der Holt B, Smitt PS, et al. CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies. Neurology. 2007;68(20):1674-9.
9. Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012; 118(11):2944-51.
10. Tai WM, Chung J, Tang PL, Koo YX, Hou X, Tay KW, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol. 2011;90(7):809-18.
11. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol. 2009;89(5):577-83.
12. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-52.
13. Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, et al. CNS disease in younger patients with aggressive Bcell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5):1267-73.
14. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99(8):2685-93.
15. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26(16):2717-24.
16. Swerdlow SH, Campo E, Harris NL, Campo E, Harris NL, Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
17. Kraan J, Gratama JW, Haioun C, Orfao A, Plonquet A, Porwit A, et al. Flow cytometric immunophenotyping of cerebrospinal fluid. Curr Protoc Cytom. 2008;Chapter 6:Unit 6 25.
18. Glass B, Kloess M, Bentz M, Schlimok G, Berdel WE, Feller A, et al. Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive highrisk non-Hodgkin lymphoma. Blood. 2006;107(8):3058-64.
19. Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97(5):758-65.
20. Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996;14(3):925-34.
21. Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999; 17(8):2461-70.
22. Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Loffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87(2): 495-508.
23. Agresti A. Categorical data analysis. New York: John Wiley and Sons, Inc., 1990.
24. Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516--the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-9.
25. Sancho JM, Orfao A, Quijano S, Garcia O, Panizo C, Perez-Ceballos E, et al. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol. 2010;85(4): 321-8.
26. Benevolo G, Stacchini A, Spina M, Ferreri AJ, Arras M, Bellio L, et al. Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood. 2012;120(16):3222-8.
27. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17): 3896-902.
28. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466-8.
29. Feugier P, Virion JM, Tilly H, Haioun C, Marit G, Macro M, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol. 2004;15(1):129-33.